|
Acquisition of King Pharmaceuticals Inc - Pro Forma Information (Detail) (King [Member], Pro Forma Consolidated Results [Member], USD $)
In Millions, except Per Share data |
3 Months Ended | 6 Months Ended | |
|---|---|---|---|
|
Jul. 04, 2010
|
Jul. 03, 2011
|
Jul. 04, 2010
|
|
|
King [Member] | Pro Forma Consolidated Results [Member]
|
|||
| Business Acquisition [Line Items] | |||
| Revenues | $ 17,465 | $ 33,595 | $ 34,414 |
| Income from continuing operations attributable to Pfizer Inc. common shareholders | $ 2,408 | $ 5,008 | $ 4,314 |
| Diluted earnings per share attributable to Pfizer Inc. common shareholders | $ 0.30 | $ 0.63 | $ 0.53 |
| X | ||||||||||
|
- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
|
| X | ||||||||||
|
- Definition
The pro forma income from continuing operations before changes in accounting and extraordinary items, net of tax effect, per diluted share of common stock for a period as if the business combination or combinations had been completed at the beginning of a period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The pro forma income from continuing operations before changes in accounting and extraordinary items, net of tax effect, for the period as if the business combination or combinations had been completed at the beginning of a period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|